Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Jean‐Sébastien Frenel"'
Did the COVID-19 pandemic delay treatment for localized breast cancer patients? A multicenter study.
Autor:
Ke Zhou, Marie Robert, Valérie Seegers, Audrey Blanc-Lapierre, Stéphane Savouroux, Frédéric Bigot, Jean-Sébastien Frenel, Mario Campone, Thierry Conroy, Frédérique Penault-Llorca, Jean-Luc Raoul, Martine M Bellanger
Publikováno v:
PLoS ONE, Vol 19, Iss 5, p e0304556 (2024)
BackgroundLonger times between diagnosis and treatments of cancer patients have been estimated as effects of the COVID-19 pandemic. However, relatively few studies attempted to estimate actual delay to treatment at the patient level.ObjectiveTo asses
Externí odkaz:
https://doaj.org/article/dc5daa6a832b496198b0d922d82d61ff
Autor:
Nour‐El‐Houda Mourksi, Cécile Dalban, Amélie Colombe‐Vermorel, Laetitia Odeyer, Valentin Simioni, Jean‐Sébastien Frenel, Michel Fabbro, Fernando Bazan, Sophie Abadie‐Lacourtoisie, Elodie Coquan, Séverine Martinez, Gwenaelle Garin, Séverine Tabone‐Eglinger, Isabelle Treilleux, Sylvie Chabaud, David Pérol, Isabelle Ray‐Coquard, Pierre‐Etienne Heudel, Jean‐Jacques Diaz, Virginie Marcel
Publikováno v:
Molecular Oncology, Vol 17, Iss 1, Pp 27-36 (2023)
Resistance of advanced hormone‐dependent endometrial carcinoma to endocrine therapy remains a worldwide clinical issue. We recently reported that the combination of Vistusertib (V, mTOR inhibitor) and Anastrozole (A, aromatase inhibitor) improves t
Externí odkaz:
https://doaj.org/article/ae737b53e2ab4d899bf43ee577ab684b
Autor:
Sue Cheeseman, Bethany Levick, Will Sopwith, Hayley Fenton, Eun Ji Nam, DongKyu Kim, Subin Lim, Elodie Martin, Jean-Sébastien Frenel, François Bocquet, Paul Kubelac, Patriciu Achimas-Cadariu, Catalin Vlad, Marion Chevrier, Roman Rouzier, Matthieu Carton, Joana Savva-Bordalo, Marta Magalhães, Marina Borges, Andrea Wolf, Sven Becker, Nicolas Niklas, Mariana Guergova-Kuras, Geoff Hall
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionMuch drug development and published analysis for epithelial ovarian cancer (EOC) focuses on early-line treatment. Full sequences of treatment from diagnosis to death and the impact of later lines of therapy are rarely studied. We describe
Externí odkaz:
https://doaj.org/article/26bf76eb219844d9bb87a849e19e5890
Autor:
Loïg Vaugier, Loïc Ah-Thiane, Maud Aumont, Emmanuel Jouglar, Mario Campone, Camille Colliard, Ludovic Doucet, Jean-Sébastien Frenel, Carole Gourmelon, Marie Robert, Stéphane-André Martin, Tanguy Riem, Vincent Roualdes, Loïc Campion, Augustin Mervoyer
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
Abstract Glioblastoma (GBM) is frequent in elderly patients, but their frailty provokes debate regarding optimal treatment in general, and the standard 6-week chemoradiation (CRT) in particular, although this is the mainstay for younger patients. All
Externí odkaz:
https://doaj.org/article/9959c315a95c4f11991a2ba7dba0e39b
Autor:
Mathilde Colombié, Pascal Jézéquel, Mathieu Rubeaux, Jean-Sébastien Frenel, Frédéric Bigot, Valérie Seegers, Mario Campone
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
Abstract Background Breast cancer is the most common cancer in women and the first cancer concerning mortality. Metastatic breast cancer remains a disease with a poor prognosis and about 30% of women diagnosed with an early stage will have a secondar
Externí odkaz:
https://doaj.org/article/a8460bd3abbf4701b7f1fdd98a7d5b53
Autor:
Nina Guyon, Delphine Garnier, Joséphine Briand, Arulraj Nadaradjane, Gwenola Bougras-Cartron, Judith Raimbourg, Mario Campone, Dominique Heymann, François M. Vallette, Jean-Sébastien Frenel, Pierre-François Cartron
Publikováno v:
Cell Death and Disease, Vol 11, Iss 12, Pp 1-11 (2020)
Abstract Anti-PD1 immunotherapy, as a single agent or in combination with standard chemotherapies, has significantly improved the outcome of many patients with cancers. However, resistance to anti-PD1 antibodies often decreases the long-term therapeu
Externí odkaz:
https://doaj.org/article/a9df5a188ee4453c9e09d42ff5c0c69d
Autor:
Marcela Carausu, Matthieu Carton, Luc Cabel, Anne Patsouris, Christelle Levy, Benjamin Verret, David Pasquier, Marc Debled, Anthony Gonçalves, Isabelle Desmoulins, Isabelle Lecouillard, Thomas Bachelot, Jean-Marc Ferrero, Jean-Christophe Eymard, Marie-Ange Mouret-Reynier, Michaël Chevrot, Eleonora De Maio, Lionel Uwer, Jean-Sébastien Frenel, Marianne Leheurteur, Thierry Petit, Amélie Darlix, Laurence Bozec
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Background: As a result of progress in diagnosis and treatment, there is a growing prevalence of metastatic breast cancer (MBC) with isolated CNS metastases. This study describes the largest-to-date real-life cohort of this clinical setting and compa
Externí odkaz:
https://doaj.org/article/3571edce971847b49f7c849370e26425
Autor:
Arulraj Nadaradjane, Joséphine Briand, Gwenola Bougras-Cartron, Valentine Disdero, François M. Vallette, Jean-Sébastien Frenel, Pierre-François Cartron
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 13, Iss , Pp 642-650 (2018)
In the last decade, microRNAs (miRs) have been described as biomarkers and therapeutic agents. Based on this finding, our aim here is to know if (1) miRNA-370-3p can be used as a biomarker associated with a favorable survival and if (2) miRNA-370-3p
Externí odkaz:
https://doaj.org/article/7362bc54b37f4aadb1a5de236436990f
Autor:
Manon Duforestel, Arulraj Nadaradjane, Gwenola Bougras-Cartron, Joséphine Briand, Christophe Olivier, Jean-Sébastien Frenel, François M. Vallette, Sophie A. Lelièvre, Pierre-François Cartron
Publikováno v:
Frontiers in Genetics, Vol 10 (2019)
The acknowledgment that pollutants might influence the epigenome raises serious concerns regarding their long-term impact on the development of chronic diseases. The herbicide glyphosate has been scrutinized for an impact on cancer incidence, but rep
Externí odkaz:
https://doaj.org/article/f00f1fca75874703aa8080106019d370
Publikováno v:
Hepatic Oncology, Vol 6, Iss 1 (2019)
Most hepatocellular carcinoma patients could not benefit from or experience disease recurrence after curative treatments. In 2007 sorafenib demonstrated efficacy in first line treatment of advanced hepatocellular carcinoma. After a decade of negative
Externí odkaz:
https://doaj.org/article/117045c4049f4a3cbde8e9e06009b690